UK Biobank guideline review links higher UMOD levels to lower aortic regurgitation progression risk

Photo by Louis Reed / Unsplash

Frontiers in Medicine Published May 14, 2026 Medically reviewed May 14, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that higher UMOD levels associate with lower AVR risk in aortic regurgitation.

This publication is a guideline-supported observational cohort study utilizing data from the UK Biobank. The research focuses on individuals with aortic regurgitation to assess the relationship between circulating UMOD levels and clinical outcomes. The study compares UMOD against conventional renal markers including creatinine, urea, and microalbumin.

Key findings indicate that higher circulating UMOD levels were independently associated with a lower risk of subsequent aortic valve replacement. The adjusted hazard ratio per standard deviation was 0.57 with a 95% CI of 0.34–0.98 and a p-value of 0.041. Additionally, UMOD levels showed a strong association with lower arterial stiffness, with a beta of -5.32 and a p-value less than 0.001.

The authors note that prior studies have predominantly focused on advanced disease stages and post-interventional outcomes, with limited data on pre-interventional progression. As an observational study, the data does not support causal claims beyond the biological context provided. The practice relevance is that Uromodulin as a genetically anchored biomarker stratifies time to valve intervention in aortic regurgitation.

Study Details

Study typeGuideline

EvidenceLevel 5

PublishedMay 2026

View Original Abstract ↓

BackgroundAortic regurgitation (AR) frequently remains asymptomatic for prolonged periods, with guideline recommendations for intervention largely guided by imaging-based assessment of left ventricular remodeling. While renal dysfunction has been linked to adverse outcomes in AR, prior studies have predominantly focused on advanced disease stages and post-interventional outcomes, with limited data on pre-interventional progression, offering limited insight into pre-interventional disease progression or biologically informed approaches to risk stratification.MethodsWe investigated renal biomarkers in individuals with AR from the UK Biobank (n = 2,493) and assessed associations with time to aortic valve replacement (AVR) using Cox proportional hazards models. Associations with cardiovascular imaging and hemodynamic phenotypes were examined via logistic regression. To place clinical findings in a biological context, we performed genome-wide colocalization analyses between AR phenotypes, blood pressure, and renal traits, followed by regulatory annotation, single-cell RNA sequencing (Kidney Cell Atlas), and phenome-wide association analyses.ResultsAmong patients with AR, higher circulating UMOD levels were independently associated with a lower risk of subsequent AVR (adjusted HR per SD 0.57, 95% CI 0.34–0.98; p = 0.041), whereas conventional renal markers (creatinine, urea, microalbumin) showed no association. UMOD levels were strongly associated with lower arterial stiffness (β = −5.32 ± 0.27; p